Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07610005 | A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants | PHASE1 | RECRUITING | 20 | — | — | May 21, 2026 | Jun 1, 2026 | Jun 8, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Reference Formulation, then Test Formulation | EXPERIMENTAL | - |
| Test Formulation, then Reference Formulation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Varegacestat Reference Formulation | DRUG | Oral administration |
| Varegacestat Test Formulation | DRUG | Oral administration |
Inclusion Criteria: * Healthy, adult, female of non childbearing potential or male, 18 to 55 years of age, inclusive, at the screening visit * Male participants must follow protocol-specified contraception guidance * Continuous non-smoker who has not used nicotine and tobacco containing products fo...